AI assistant
USCOM LIMITED — Regulatory Filings 2013
Jun 24, 2013
65979_rns_2013-06-24_4ec569ec-46fb-4532-b724-58bd95354f6a.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au
M A R K E T A N N O U N C E M E N T
Uscom Announces Italian Distribution Deal with Vega
Tuesday 25th of June 2013: Uscom (ASX code: UCM).
Uscom Limited today announced the completion of a distribution agreement with Vega S.p.A. to distribute USCOM products in Italy and nearby jurisdictions.
Vega S.p.A have specialized in the distribution of high technology medical devices since 1983. They provide Italian and regional distribution of precision medical instruments, equipment and machines, and devices for medical surgical and scientific applications principally in the hospital market and particularly in cardiology. Vega S.p.A also provide high level technical product support as part of their distribution commitment.
Executive Chairman of Uscom, Rob Phillips said, “We are delighted to welcome Vega S.p.A on board as part of our new drive to optimise global distribution. We now manufacture and market premium products into the cardiac output space, the USCOM line of products, and into blood pressure monitoring, the BP+ suprasystolic central blood pressure monitoring line of products, and are now developing reliable distribution of these technologies worldwide. We are currently negotiating a number of new relationships and seeking new worldwide partners to extend our distribution depth and reach.”
Uscom Limited manufacture accurate noninvasive devices for measurements of cardiac and vascular function. The USCOM 1A is an innovative and practice leading cardiac output monitor with application in Emergency Medicine, Critical Care Medicine, Paediatrics, and septic shock and fluid management. The Uscom BP+ is a unique and simple blood pressure monitoring device which uses suprasystolic oscillometry to measure blood pressure waves at the level of the heart. This central blood pressure measurement is considered more accurate than measurements of blood pressure in the arm and has application in the ICU, the ED, Paediatrics, military and retrieval applications, general ward, medical clinics, research applications and home blood pressure monitoring.
References:
Roman MJ, Devereaux RB, Kizer JR, Okin PM, Lee ET, Wang W, Umans JG, Calhoun D, Howard BV. High Central Pulse Pressure is Independently Associated With Adverse Cardiovascular Outcome. The Strong Heart Study. Journal of the American College of Cardiology 2009;15(18):1730-1734. Doi:10.1016/j.jacc.2009.05.070. Roman MJ. Central blood pressure: A new vital sign? Artery Research 2009(3):125-127.
Uscom Limited
ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au
M A R K E T A N N O U N C E M E N T
About Uscom
Uscom Limited is an ASX listed cardiovascular medical device company (UCM). Uscom manufactures and markets a Non Invasive Ultrasonic Cardiac Output Monitor, the USCOM 1A, and a Central Blood Pressure Monitor, the BP+. The devices have global regulatory approval and USCOM is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.
The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.
The Uscom BP+ technology provides simple to use, and highly accurate and repeatable measurement of Central Blood Pressure, measuring both brachial and central blood pressure waveforms quickly, consistently and simply using noninvasive suprasystolic oscillometry combined with a familiar upper arm cuff. The BP+ is simple to use and requires no complex training to provide reliable measurement of Augmentation Index and Arterial stiffness, pulse rate variability and signal quality indices. For more information, please visit: www.uscom.com.au, www.pulsecor.com
Uscom Contacts Rob Phillips Executive Chairman [email protected]
Sarah Prince Company Secretary [email protected]